INOZYME PHARMA, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 28th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between Inozyme Pharma, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiveness of a Registration Statement on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock].
OPEN MARKET SALE AGREEMENTSMInozyme Pharma, Inc. • August 11th, 2021 • Pharmaceutical preparations • New York
Inozyme Pharma, Inc. STOCK OPTION AGREEMENTStock Option Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
June 30, 2020 Steven Jungles Dear Steve:Letter Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This letter (the “Letter Agreement”) amends and restates the terms and conditions of your employment with Inozyme Pharma, Inc. (“Inozyme” or the “Company”), as initially set forth in the offer letter dated April 18, 2017 and as amended if applicable (the “Original Offer Letter”), and will be effective as of the date on which the registration statement relating to the Company’s initial public offering is effective (the “Effective Date”), provided that you remain employed by the Company as of the Effective Date. Until the Effective Date, the Original Offer Letter will remain in full force and effect and continue to govern your employment with the Company. This Letter Agreement contains the following terms:
Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
INOZYME PHARMA, INC. STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLANStock Option Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations
This Stock Option Agreement (this “Agreement”) is made between Inozyme Pharma, Inc., a Delaware corporation (the “Company”), and the Participant pursuant to the Amended and Restated 2017 Equity Incentive Plan (the “Plan”).
March 14, 2023 (revised) Matthew Winton, PhD Dear Matthew:Inozyme Pharma, Inc. • May 9th, 2023 • Pharmaceutical preparations • Massachusetts
On behalf of Inozyme Pharma Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Letter Agreement”) is to summarize the terms of your employment with the Company, should you accept our offer:
INOZYME PHARMA, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), dated as of November 9, 2018, by and among INOZYME PHARMA, INC., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto (referred to hereinafter as the “Investors” and each individually as an “Investor”) amends and restates the Amended and Restated Investor Rights Agreement entered into as of April 13, 2017, by and among the Company and the Investors (defined therein) party thereto (the “Prior Agreement”).
Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENT Granted under 2023 Inducement Stock Incentive PlanRestricted Stock Unit Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Consulting AgreementConsulting Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Inozyme Pharma, Inc. (the “Company”) and Axel Bolte (the “Consultant”).
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
THIS LICENSE AGREEMENT (this “AGREEMENT”), dated as of January 6, 2017 (the “EFFECTIVE DATE”), by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and INOZYME PHARMA, LLC, a limited liability company formed and existing under the laws of the State of Delaware, and with principal offices located at [**] (“LICENSEE”) is effective as of the EFFECTIVE DATE.
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL...Corporate Sponsored Research Agreement • March 12th, 2024 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017 (the “Effective Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”), and Inozyme Pharma, LLC, a Delaware limited liability company, having its principal offices at 240 Bluff View Drive, Guilford, Connecticut 06347 (the “Sponsor”).
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL...Corporate Sponsored Research Agreement • March 15th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017 (the “Effective Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”), and Inozyme Pharma, LLC, a Delaware limited liability company, having its principal offices at 240 Bluff View Drive, Guilford, Connecticut 06347 (the “Sponsor”).
INOZYME PHARMA, LLC REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT, dated as of June 1, 2016 (this “Agreement”), by and among Inozyme Pharma, LLC, a Delaware limited liability company (the “Company”), and holders of the Company’s Class 1 Stock (the “Class 1 Stock”), listed on Exhibit A (together with certain other persons who become parties as provided herein, the “Holders”).
March 24, 2021 Stephen Basso Dear Stephen:Original Letter Agreement • March 25th, 2021 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This letter (the “Letter Agreement”) amends and restates the terms and conditions of your employment with Inozyme Pharma, Inc. (“Inozyme” or the “Company”), as set forth in your letter agreement dated June 30, 2020 (the “Original Letter Agreement”), and will be effective as of March 24, 2021 (the “Effective Date”), provided that you remain employed by the Company as of the Effective Date. Until the Effective Date, the Original Letter Agreement will remain in full force and effect and continue to govern your employment with the Company. This Letter Agreement contains the following terms:
CONSULTING AGREEMENTConsulting Agreement • March 15th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the “Agreement”) is entered into and effective as of November 30, 2021 (the “Effective Date”), by and between Inozyme Pharma, Inc., a Delaware corporation having a place of business at 321 Summer Street, Suite 400, Boston, MA 02210 (the “Company”), and Wenkert & Young, LLC, a limited liability company having a place of business at [**] (the “Consultant” and Company and Consultant, each, individually a “Party” and collectively, the “Parties”). In consideration of the mutual covenants set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • May 7th, 2021 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Consulting Agreement (the “Agreement”) is made effective as of May 4, 2021 (the “Effective Date”), by and between Inozyme Pharma, Inc., a Delaware corporation, with its principal place of business being 321 Summer Street, Suite 400, Boston, MA 02210(the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”), which amends and restates that certain Consulting Agreement, dated January 21, 2016, by and among the Company and Danforth, as amended from time to time (the “Original Agreement”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”
INOZYME PHARMA, LLC RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS RESTRICTED STOCK AGREEMENT, dated as of the date set forth on Exhibit A hereto (this “Agreement”), by and between Inozyme Pharma, LLC, a Delaware limited liability company (the “Company”), and the person named in Exhibit A hereto (the “Purchaser”).
Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENT Granted under 2020 Stock Incentive PlanRestricted Stock Unit Agreement • March 12th, 2024 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EXECUTIVE TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENTRelease of Claims Agreement • December 8th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Transition, Separation, and Release of Claims Agreement (the “Agreement”) is made as of December 7, 2022 (the “Effective Date”) by and between Inozyme Pharma, Inc. (the “Company”) and Henric Bjarke (the “Executive”) (together, the “Parties”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INTELLECTUAL PROPERTY ASSET...Intellectual Property Asset Purchase Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS INTELLECTUAL PROPERTY ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 17, 2020 (the “Effective Date”) by and between Inozyme Pharma, Inc., a Delaware corporation with its principal office at 321 Summer Street, Floor 4, Boston, MA 02210 (the “Buyer”), on the one hand, and Alexion Pharmaceuticals, Inc., a Delaware corporation, with its principal office at 121 Seaport Boulevard, Boston, MA 02210 (the “Seller”, with Seller and Buyer each, individually, a “Party” and, collectively, the “Parties”), on the other hand.
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL...Corporate Sponsored Research Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017 (the “Effective Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”), and Inozyme Pharma, LLC, a Delaware limited liability company, having its principal offices at [**] (the “Sponsor”).
Employment contractEmployment Contract • March 25th, 2021 • Inozyme Pharma, Inc. • Pharmaceutical preparations
WHEREAS, Inozyme Pharma, Inc, 321 Summer Street, Suite 400 Boston, MA 02210, USA, (the “Parent”) and the Employee have concluded an employment agreement on 30 June 2020 (the “Prior Employment Agreement”);
VIA ELECTRONIC MAIL November 3, 2021 (as revised on November 30, 2021) Deborah Wenkert, MD Dear Deb:Consulting Agreement • March 15th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • California
As we have discussed, you are separating from employment with Inozyme Pharma, Inc. (the “Company”) for good reason, effective November 30, 2021 (the “Separation Date”). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you materially comply with the terms and conditions of this letter agreement, sign and return this letter agreement to me on, but not before, the Separation Date, and do not revoke your agreement (as described below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least twenty-one (21) days to do so. If you sign this letter agreement, you may change y
Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston, Massachusetts 02210Letter Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
On behalf of Inozyme Pharma Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Letter Agreement”) is to summarize the terms of your employment with the Company, should you accept our offer:
Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston, Massachusetts 02210Inozyme Pharma, Inc. • May 9th, 2023 • Pharmaceutical preparations
As we have discussed, you are retiring and resigning from employment with Inozyme Pharma Switzerland GmbH (the “Company”), effective April 30, 2023 (the “Separation Date”). By countersigning and returning this letter agreement, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3. The severance benefits described in paragraph 2 below will be subject to you adhering to this letter agreement and returning a signed waiver in the form of Annex 1 on but not earlier than May 31, 2023 and not revoking your agreement to the waiver in Annex 1 (as described below) during the seven (7) day period after you have signed or timely revoking paragraph 4(b) below, in either case by notifying me in writing.
Inozyme Pharma, Inc. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2023 Inducement Stock Incentive PlanNonstatutory Stock Option Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
